TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Top Page
TOT BIOPHARM International Co. Ltd.
(1875)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$4.50
▲(80.00% Upside)
Action:ReiteratedDate:01/16/26
The score is driven primarily by improved financial performance (stronger profitability and a solid balance sheet), while the biggest offsets are extremely overbought technical conditions (RSI 96.9) and very expensive valuation (P/E ~399).
Positive Factors
Balance sheet strength
A relatively low debt-to-equity ratio and stable equity base provide durable financial flexibility for R&D and commercialization cycles. Strong balance sheet reduces refinancing and solvency risk, enabling continued investment in drug development and strategic partnerships over the next several quarters.
Negative Factors
Persistent negative free cash flow
Continued negative free cash flow signals that operating cash generation does not yet cover capital and growth spending, raising liquidity and financing risk. Over several months this can force external financing or cutbacks in R&D/commercialization, constraining strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A relatively low debt-to-equity ratio and stable equity base provide durable financial flexibility for R&D and commercialization cycles. Strong balance sheet reduces refinancing and solvency risk, enabling continued investment in drug development and strategic partnerships over the next several quarters.
Read all positive factors
TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.86B
Dividend YieldN/A
Average Volume (3M)240.51K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth9.41%
EPS Growth-32.69%
CountryHK
Employees611
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)1.67
Price to Sales (P/S)1.11
P/FCF Ratio-170.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$1.61B
TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model
Company Description
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The co...
How the Company Makes Money
TOT BIOPHARM generates revenue primarily through the sale of its biopharmaceutical products, which include proprietary drugs and therapies developed in-house. The company has a diverse revenue model that includes direct sales to hospitals and clin...
TOT BIOPHARM International Co. Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07B | 1.10B | 780.63M | 442.18M | 76.33M | 22.49M |
| Gross Profit | 758.56M | 782.43M | 573.99M | 370.62M | 27.47M | 15.53M |
| EBITDA | 43.83M | 84.96M | 10.45M | -5.41M | -224.51M | -254.71M |
| Net Income | 7.26M | 34.76M | -37.76M | -49.92M | -261.22M | -288.50M |
Balance Sheet | ||||||
| Total Assets | 1.48B | 1.51B | 1.43B | 1.26B | 710.26M | 641.18M |
| Cash, Cash Equivalents and Short-Term Investments | 383.98M | 381.26M | 351.60M | 517.63M | 155.38M | 225.53M |
| Total Debt | 397.20M | 395.47M | 345.65M | 289.53M | 208.56M | 7.41M |
| Total Liabilities | 744.74M | 779.12M | 739.41M | 546.59M | 375.17M | 58.83M |
| Stockholders Equity | 731.68M | 729.65M | 686.69M | 713.88M | 335.09M | 582.36M |
Cash Flow | ||||||
| Free Cash Flow | 48.42M | -7.17M | -146.77M | -180.19M | -290.45M | -285.30M |
| Operating Cash Flow | 123.43M | 116.40M | 56.43M | 59.93M | -175.14M | -263.12M |
| Investing Cash Flow | -80.23M | -122.50M | -164.10M | -282.76M | -108.39M | 12.53M |
| Financing Cash Flow | -7.09M | 34.18M | 38.23M | 481.24M | 212.08M | -61.71M |
TOT BIOPHARM International Co. Ltd. Technical Analysis
Positive
2.50
Price Trends
4.42
Positive
3.30
Positive
2.73
Positive
Market Momentum
0.32
Positive
55.18
Neutral
29.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Positive. The current price of 2.5 is below the 20-day moving average (MA) of 4.82, below the 50-day MA of 4.42, and below the 200-day MA of 2.73, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 55.18 is Neutral, neither overbought nor oversold. The STOCH value of 29.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1875.
TOT BIOPHARM International Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.67B | -7.14 | -12.64% | ― | -38.38% | -22.12% | |
46 Neutral | HK$1.66B | -5.33 | -39.41% | ― | ― | 47.42% | |
45 Neutral | HK$2.06B | 33.28 | 43.89% | ― | 178.36% | 86.74% | |
44 Neutral | HK$1.01B | -18.55 | -15.19% | ― | ― | 22.65% | |
43 Neutral | HK$1.68B | -6.43 | 293.08% | ― | ― | 27.90% |
* Healthcare Sector Average
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.41
214.47%
HK:2181
Mabpharm Limited
0.50
0.05
11.11%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.13
2.27
122.04%
HK:6622
Zhaoke Ophthalmology Ltd.
3.04
1.58
108.22%
HK:6978
Immunotech Biopharm Ltd
2.72
-0.40
-12.82%
HK:2511
Hightide Therapeutics Inc
3.26
2.02
162.90%
TOT BIOPHARM International Co. Ltd. Corporate Events
TOT BIOPHARM Receives Voluntary Cash Offer at 99% Premium
Jan 14, 2026
Citigroup Global Markets Asia Limited will, on behalf of an offeror, launch voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd. not already owned by the offeror and its concert parties at HK$4.00 p...
BioDlink Clarifies Pre-IPO Share Option Scheme and Expiry in Supplemental Annual Report
Dec 31, 2025
BioDlink International Company Limited has issued a supplemental announcement to its 2024 annual report, providing additional details on its Pre-IPO Share Option Scheme and related equity incentive plans as required under Hong Kong listing rules. ...
BioDlink Requests Trading Halt Pending Inside Information Announcement
Dec 29, 2025
BioDlink International Company Limited, a Hong Kong-incorporated company listed on the Hong Kong Stock Exchange (stock code 1875), announced the composition of its board, comprising an executive director, a non-executive director and three indepen...
BioDlink Grants 13.35 Million Restricted Shares to Staff Under 2024 Incentive Scheme
Dec 21, 2025
BioDlink International Company Limited has granted 13,350,000 restricted share awards, equivalent to about 1.73% of its issued share capital, to eight non-director employees under its 2024 Restricted Share Award Scheme. The awards, priced at HK$0....
BioDlink Reports 23% Revenue Decline Amidst Market Competition
Nov 11, 2025
BioDlink International Company Limited, along with its subsidiaries, operates in the biotechnology sector, focusing on the development and commercialization of biopharmaceutical products. The company is listed on the Hong Kong Stock Exchange and h...
BioDlink Announces Leadership Changes Amidst Resignations
Oct 16, 2025
BioDlink International Company Limited announced changes in its leadership, with Dr. Liu and Ms. Yeh-Huang resigning from their respective positions due to family reasons. This reshuffling may impact the company’s strategic direction and gov...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.